SUVENPHAR2023-04-012023-06-30 SUVENPHAR2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2023-04-012023-06-30in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2023-06-30 SUVENPHAR2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543064 SUVENPHAR NOTLISTED Suven Pharmaceuticals Limited Equity 2023-04-01 2024-03-31 2023-08-08 2023-08-01 INR Lakhs First quarter 15:00:00 16:00:00 2023-08-08 2023-08-08 false Not applicable Single segment Contract Development and Manufacturing Operations (CDMO) 2023-04-01 2023-06-30 Unaudited Consolidated 3475501000.00 106651000.00 3582152000.00 797718000.00 0.00 214998000.00 287440000.00 11465000.00 125412000.00 505688000.00 1942721000.00 1639431000.00 0.00 1639431000.00 413107000.00 20425000.00 433532000.00 0.00 1205899000.00 0.00 0.00 0.00 0.00 1205899000.00 91000.00 1205990000.00 0.00 0.00 0.00 0.00 254565000.00 1 4.74 4.74 0.00 0.00 4.74 4.74 Notes: 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th August, 2023.The results for the for the quarter ended 30th June , 2023 has been reviewed by our statutory auditors. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, lnc.,USA & Casper Pharma Pvt Ltd. 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022. 6) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Manufacturing Expenses 322753000.00 Other Expenses 162055000.00 R & D Expenses 20880000.00 Items that will not be reclassified to profit or loss 121000.00 121000.00 30000.00 0.00